Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients
Objectives. Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2020/6653851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547164628189184 |
|---|---|
| author | Yutaka Kawabata Takeshi Soeki Hiroyuki Ito Tomomi Matsuura Kenya Kusunose Takayuki Ise Koji Yamaguchi Takeshi Tobiume Shusuke Yagi Daiju Fukuda Hirotsugu Yamada Tetsuzo Wakatsuki Mitsuhiro Kitani Kazuhiro Kawano Yoshio Taketani Masataka Sata |
| author_facet | Yutaka Kawabata Takeshi Soeki Hiroyuki Ito Tomomi Matsuura Kenya Kusunose Takayuki Ise Koji Yamaguchi Takeshi Tobiume Shusuke Yagi Daiju Fukuda Hirotsugu Yamada Tetsuzo Wakatsuki Mitsuhiro Kitani Kazuhiro Kawano Yoshio Taketani Masataka Sata |
| author_sort | Yutaka Kawabata |
| collection | DOAJ |
| description | Objectives. Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing the RAS. Methods. A total of 25 hypertensive patients receiving a RAS inhibitor were randomly assigned to a cilnidipine (n = 12) or amlodipine (n = 13) group. The effects of cilnidipine on proteinuria and angiotensin II–renin feedback were assessed. Results. After 6 months of treatment, both systolic and diastolic blood pressures were significantly reduced to a similar extent in both groups. The urine albumin-to-creatinine ratio was significantly lower in the cilnidipine group (p<0.05) than in the amlodipine group. Amlodipine increased plasma angiotensin I and angiotensin II levels (p<0.05), whereas cilnidipine did not. Interestingly, the cilnidipine group had a higher ratio of angiotensin-(1–7) (Ang-(1–7)) to angiotensin II in plasma than the amlodipine group (p<0.05). Conclusions. The L-/N-type CCB cilnidipine, but not amlodipine, decreased urinary albumin excretion in hypertensive patients. Cilnidipine also increased the ratio of Ang-(1–7) to angiotensin II in plasma, which might be one factor underlying its beneficial effects. |
| format | Article |
| id | doaj-art-97ba57c5340346dba613ea462f9b7a0e |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-97ba57c5340346dba613ea462f9b7a0e2025-02-03T06:45:51ZengWileyInternational Journal of Hypertension2090-03842090-03922020-01-01202010.1155/2020/66538516653851Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive PatientsYutaka Kawabata0Takeshi Soeki1Hiroyuki Ito2Tomomi Matsuura3Kenya Kusunose4Takayuki Ise5Koji Yamaguchi6Takeshi Tobiume7Shusuke Yagi8Daiju Fukuda9Hirotsugu Yamada10Tetsuzo Wakatsuki11Mitsuhiro Kitani12Kazuhiro Kawano13Yoshio Taketani14Masataka Sata15Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Community Medicine for Cardiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanDepartment of Cardiovascular Medicine, Kagawa Prefectural Shirotori Hospital, Higashikagawa, JapanDepartment of Cardiovascular Medicine, Yoshinogawa Medical Center, Yoshinogawa, JapanDepartment of Cardiovascular Medicine, Shikoku Medical Center for Children and Adults, Zentsuji, JapanDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, JapanObjectives. Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing the RAS. Methods. A total of 25 hypertensive patients receiving a RAS inhibitor were randomly assigned to a cilnidipine (n = 12) or amlodipine (n = 13) group. The effects of cilnidipine on proteinuria and angiotensin II–renin feedback were assessed. Results. After 6 months of treatment, both systolic and diastolic blood pressures were significantly reduced to a similar extent in both groups. The urine albumin-to-creatinine ratio was significantly lower in the cilnidipine group (p<0.05) than in the amlodipine group. Amlodipine increased plasma angiotensin I and angiotensin II levels (p<0.05), whereas cilnidipine did not. Interestingly, the cilnidipine group had a higher ratio of angiotensin-(1–7) (Ang-(1–7)) to angiotensin II in plasma than the amlodipine group (p<0.05). Conclusions. The L-/N-type CCB cilnidipine, but not amlodipine, decreased urinary albumin excretion in hypertensive patients. Cilnidipine also increased the ratio of Ang-(1–7) to angiotensin II in plasma, which might be one factor underlying its beneficial effects.http://dx.doi.org/10.1155/2020/6653851 |
| spellingShingle | Yutaka Kawabata Takeshi Soeki Hiroyuki Ito Tomomi Matsuura Kenya Kusunose Takayuki Ise Koji Yamaguchi Takeshi Tobiume Shusuke Yagi Daiju Fukuda Hirotsugu Yamada Tetsuzo Wakatsuki Mitsuhiro Kitani Kazuhiro Kawano Yoshio Taketani Masataka Sata Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients International Journal of Hypertension |
| title | Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients |
| title_full | Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients |
| title_fullStr | Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients |
| title_full_unstemmed | Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients |
| title_short | Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients |
| title_sort | effects of l n type calcium channel blockers on angiotensin ii renin feedback in hypertensive patients |
| url | http://dx.doi.org/10.1155/2020/6653851 |
| work_keys_str_mv | AT yutakakawabata effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT takeshisoeki effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT hiroyukiito effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT tomomimatsuura effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT kenyakusunose effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT takayukiise effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT kojiyamaguchi effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT takeshitobiume effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT shusukeyagi effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT daijufukuda effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT hirotsuguyamada effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT tetsuzowakatsuki effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT mitsuhirokitani effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT kazuhirokawano effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT yoshiotaketani effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients AT masatakasata effectsoflntypecalciumchannelblockersonangiotensiniireninfeedbackinhypertensivepatients |